Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO
June 1 (Reuters) - Allogene Therapeutics Inc ALLO.O:
ALLOGENE THERAPEUTICS PROVIDES UPDATED PHASE 1 DATA HIGHLIGHTING DURABLE RESPONSES WITH ALLO-316 IN HEAVILY PRETREATED ADVANCED RENAL CELL CARCINOMA AT ASCO
ALLOGENE THERAPEUTICS INC - SINGLE DOSE OF ALLO-316 ACHIEVES 31% RESPONSE RATE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.